Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: dosimetric comparison and risk assessment of solid secondary cancer

  • Bae, Sun Hyun (Department of Radiation Oncology, Soonchunhyang University Bucheon Hospital) ;
  • Kim, Dong Wook (Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong) ;
  • Kim, Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Shin, Myung-Hee (Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine) ;
  • Park, Hee Chul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Do Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2016.09.05
  • Accepted : 2016.11.17
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To determine the optimal radiotherapy technique for gastric mucosa-associated lymphoid tissue lymphoma (MALToma), we compared the dosimetric parameters and the risk of solid secondary cancer from scattered doses among anterior-posterior/ posterior-anterior parallel-opposed fields (AP/PA), anterior, posterior, right, and left lateral fields (4_field), 3-dimensional conformal radiotherapy (3D-CRT) using noncoplanar beams, and intensity-modulated radiotherapy composed of 7 coplanar beams (IMRT_co) and 7 coplanar and noncoplanar beams (IMRT_non). Materials and Methods: We retrospectively generated 5 planning techniques for 5 patients with gastric MALToma. Homogeneity index (HI), conformity index (CI), and mean doses of the kidney and liver were calculated from the dose-volume histograms. Applied the Biological Effects of Ionizing Radiation VII report to scattered doses, the lifetime attributable risk (LAR) was calculated to estimate the risk of solid secondary cancer. Results: The best value of CI was obtained with IMRT, although the HI varied among patients. The mean kidney dose was the highest with AP/PA, followed by 4_field, 3D-CRT, IMRT_co, and IMRT_non. On the other hand, the mean liver dose was the highest with 4_field and the lowest with AP/PA. Compared with 4_field, the LAR for 3D-CRT decreased except the lungs, and the LAR for IMRT_co and IMRT_non increased except the lungs. However, the absolute differences were much lower than <1%. Conclusion: Tailored RT techniques seem to be beneficial because it could achieve adjacent organ sparing with very small and clinically irrelevant increase of secondary solid cancer risk compared to the conventional techniques.

Keywords

References

  1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
  2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49. https://doi.org/10.1200/JCO.1999.17.12.3835
  3. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-64. https://doi.org/10.1200/JCO.2003.06.085
  4. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005;23:7050-9. https://doi.org/10.1200/JCO.2005.04.031
  5. Lin ML, Wirth A, Chao M, et al. Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study. Intern Med J 2007;37:172-80. https://doi.org/10.1111/j.1445-5994.2006.01291.x
  6. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol 2008;87:405-11. https://doi.org/10.1016/j.radonc.2008.02.012
  7. Gobbi PG, Corbella F, Valentino F, et al. Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. Ann Oncol 2009;20:465-8.
  8. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815-24. https://doi.org/10.1002/cncr.25226
  9. Okada H, Takemoto M, Kawahara Y, et al. A prospective analysis of efficacy and long-term outcome of radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma. Digestion 2012;86:179-86. https://doi.org/10.1159/000339497
  10. Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 2013;24:1344-51. https://doi.org/10.1093/annonc/mds623
  11. Abe S, Oda I, Inaba K, et al. A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Jpn J Clin Oncol 2013;43:917-22. https://doi.org/10.1093/jjco/hyt097
  12. Kim SW, Lim DH, Ahn YC, et al. Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2013;19:6062-8. https://doi.org/10.3748/wjg.v19.i36.6062
  13. Della Biancia C, Hunt M, Furhang E, Wu E, Yahalom J. Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys 2005;62:745-51. https://doi.org/10.1016/j.ijrobp.2004.10.025
  14. Ruben JD, Lancaster CM, Jones P, Smith RL. A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis. Int J Radiat Oncol Biol Phys 2011;81:1458-64. https://doi.org/10.1016/j.ijrobp.2010.08.008
  15. Kataria T, Sharma K, Subramani V, Karrthick KP, Bisht SS. Homogeneity index: an objective tool for assessment of conformal radiation treatments. J Med Phys 2012;37:207-13. https://doi.org/10.4103/0971-6203.103606
  16. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 2006;64:333-42. https://doi.org/10.1016/j.ijrobp.2005.09.028
  17. Schneider U, Zwahlen D, Ross D, Kaser-Hotz B. Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose. Int J Radiat Oncol Biol Phys 2005;61:1510-5. https://doi.org/10.1016/j.ijrobp.2004.12.040
  18. Schneider U, Kaser-Hotz B. Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau dose-response relationships. Radiat Environ Biophys 2005;44:235-9. https://doi.org/10.1007/s00411-005-0016-1
  19. National Academy of Sciences. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2006.
  20. Statistics Korea. Complete life-table 2012 [Internet]. Daejeon: Statistics Korea; c2016 [cited 2016 Nov 20]. Available from: http://kostat.go.kr.
  21. Luxton RW. Radiation nephritis: a long-term study of 54 patients. Lancet 1961;2:1221-4.
  22. Tanaka H, Hayashi S, Ohtakara K, Hoshi H. Hepatic dysfunction after radiotherapy for primary gastric lymphoma. J Radiat Res 2013;54:92-7. https://doi.org/10.1093/jrr/rrs062
  23. Lee IJ, Seong J, Koom WS, et al. Selection of the optimal radiotherapy technique for locally advanced hepatocellular carcinoma. Jpn J Clin Oncol 2011;41:882-9. https://doi.org/10.1093/jjco/hyr053
  24. Chen D, Wang R, Meng X, et al. A comparison of liver protection among 3-D conformal radiotherapy, intensitymodulated radiotherapy and RapidArc for hepatocellular carcinoma. Radiat Oncol 2014;9:48. https://doi.org/10.1186/1748-717X-9-48
  25. Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011;12:353-60. https://doi.org/10.1016/S1470-2045(11)70061-4
  26. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1-7. https://doi.org/10.1016/j.ijrobp.2006.01.027

Cited by

  1. Progress in the treatment of advanced gastric cancer vol.39, pp.7, 2017, https://doi.org/10.1177/1010428317714626
  2. Optimal collimator rotation based on the outline of multiple brain targets in VMAT vol.13, pp.None, 2017, https://doi.org/10.1186/s13014-018-1039-5
  3. Benefit of volumetric-modulated arc therapy over three-dimensional conformal radiotherapy for stage I-II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the stomach: a vol.36, pp.4, 2017, https://doi.org/10.3857/roj.2018.00402
  4. Combining deep-inspiration breath hold and intensity-modulated radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: Dosimetric evaluation using comprehensive plan quality indices vol.14, pp.1, 2017, https://doi.org/10.1186/s13014-019-1263-7
  5. Efficacy and Safety of Brucea javanica Oil Emulsion Injection for Treating Gastric Cancer: A Protocol for a Systematic Review and Meta Analysis vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/5236454